December 2, 2016 07:36 AM EST
R&D
Pharma

Boom­ing CRISPR pi­o­neer In­tel­lia looks to dou­ble staff with new digs

John Carroll

Editor & Founder

Mak­ing way for some am­bi­tious growth plans that in­clude dou­bling its cur­rent work force to some 200 staffers, CRISPR/Cas9 play­er In­tel­lia Ther­a­peu­tics threw a par­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times